ZappRx, a US-based mobile platform that automates the prescription management process, has closed an additional $1m in seed funding led by current investor Atlas Venture and including a new investment from SR One, the venture arm of pharmaceutical company GlaxoSmithKline.
To date, ZappRx has raised a total of $2.2M.
ZappRx will use the additional funding to further build out its prescription processing platform to meet the unique needs of the specialty pharmacy space.
Jens Eckstein, managing partner at SR One, which spent two years surveying the latest innovations in healthcare IT before choosing ZappRx, said: “As an evergreen fund backed by GSK, a major manufacturer of specialty medications, we are acutely aware of the high cost associated with manually processing specialty orders. We believe ZappRx has the ability to alleviate these inefficiencies. As an investor who strongly identifies with this problem, we want to be part of the solution.”